Altimmune (ALT) vs Relmada Therapeutics (RLMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Relmada Therapeutics (RLMD) has outperformed Altimmune (ALT) over the past year, losing 38.6% versus a loss of 72.3%. Over five years, RLMD leads with a -86.1% price change compared with -87.2% for ALT. Relmada Therapeutics is the larger company by market cap ($279.5 million vs $258.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALT | RLMD |
|---|---|---|
| Share price | $1.33 | $2.62 |
| Market cap | $258.80M | $279.54M |
| 1-day change | -5.67% | -15.76% |
| YTD return | -63.16% | -45.76% |
| 1-year return | -72.35% | -38.64% |
| 5-year return | -87.24% | -86.09% |
| EPS (TTM) | $-0.71 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $41.00K | — |
| Revenue growth (YoY) | +105.00% | — |
| Net income (latest FY) | $-88.09M | $-57.39M |
| Operating margin | -230460.98% | — |
| Net margin | -214860.98% | — |
| 52-week high | $6.44 | $8.00 |
| 52-week low | $1.32 | $2.60 |
| Distance from 52-week high | -79.35% | -67.25% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1127.82% | +310.31% |
| Average volume | 3.91M | 1.45M |
| Shares outstanding | 194.59M | 106.69M |
| Employees | 57 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLMD has outperformed ALT by 33.7 percentage points over the past year.
About Altimmune
ALT stock →Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Relmada Therapeutics
RLMD stock →Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
ALT vs RLMD FAQ
Which is bigger, Altimmune or Relmada Therapeutics?
Relmada Therapeutics (RLMD) is larger, with a market capitalization of $279.54M compared with $258.80M for Altimmune (ALT).
Which stock has performed better over the past year, ALT or RLMD?
RLMD returned -38.64% over the past 12 months, compared with -72.35% for ALT (price return, excluding dividends). Past performance does not predict future results.
Are Altimmune and Relmada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.